UPSC Darpan

Science & TechnologyGS38 October 2026

Chemistry Nobel 2026 Rewards Kagan and Soai for Making and Amplifying Molecular Handedness

Open in the app — quiz, notes, Mistake Vault हिंदी में पढ़ें

The news

Stockholm, October 7. The 2026 Chemistry Nobel goes to Henri B. Kagan, 95, of Université Paris-Sud, France, and Kenso Soai, 76, of the Tokyo University of Science, “for the discovery of non-linear effects and autocatalysis in asymmetric organic synthesis”. Many molecules are chiral: they exist in two mirror-image forms, like left and right hands. In 1986, Kagan’s team showed that a catalyst only slightly biased towards one hand could bias the product far more than expected. About a decade later, Soai found a reaction in which a chiral product catalyses more of itself, ending with 99.5% of one form. Enzymes and receptors are chiral, so a drug’s two forms can act differently. Thalidomide, a late-1950s sedative, caused birth defects across 46 countries; one form was harmful. Drugs once made as mixtures and separated expensively are now made in the wanted form directly.

The chain in one line: Life uses one hand of amino acids and sugars → laboratory reactions yield both hands equally → thalidomide shows the wrong hand can maim → Kagan shows small catalyst bias is amplified, Soai shows a product can copy its own hand → drugs and agrochemicals made in a single form

Static syllabus linkage

  1. Chirality: same atoms, mirror arrangement, different biology. Enantiomers have the same formula and bonding but are non-superimposable mirror images; a 50:50 mix is a racemic mixture. Homochirality is life’s use of a single form, as with the amino acids in proteins. The 2001 Chemistry Nobel to Knowles, Noyori and Sharpless rewarded chirally catalysed reactions.
  2. India’s bulk-drug policy is where chemistry meets self-reliance. Active pharmaceutical ingredients (APIs) are the chemicals that make a medicine work, and India imports many of them. The Production Linked Incentive scheme for critical key starting materials, drug intermediates and APIs, approved in 2020, pays incentives on incremental domestic sales; a parallel scheme supports bulk drug parks.

Why UPSC loves this

  1. Nobel science is a GS3 awareness item with a policy hook. The syllabus line is “Awareness in the fields of IT, Space, Computers, robotics, Nano-technology, bio-technology”. Examiners ask the concept and its use, not biography.

Prelims nuggets

  • The Nobel Prize in Chemistry is awarded by the Royal Swedish Academy of Sciences.
  • Enantiomers are non-superimposable mirror-image forms of a chiral molecule; an equal mixture of both is called racemic.
  • In autocatalysis, a product of a reaction acts as a catalyst for the same reaction.
  • Thalidomide, a sedative of the late 1950s, caused phocomelia, a birth defect in which limbs are shortened or absent.

Analysis

  1. The prize honours amplification, which is how chemistry becomes industry. A perfectly pure catalyst is costly to make, so Kagan’s finding that a slightly biased one can still give a strongly biased product makes single-form manufacturing affordable. Soai’s self-copying reaction shows how a tiny chance imbalance could snowball, a plausible route to life’s single-handedness, though not proof of it.
  2. Lens — Innovation and safeguards: chiral precision raises the bar for regulators. Making one form directly is cheaper and greener, but the thalidomide lesson is that the other form must still be tested, and IE notes the two thalidomide forms interconvert in the body. A regulator should therefore demand data on both forms and on purity, not just on the active ingredient.
  3. For India, the gain is in API chemistry, not formulations. India’s generics strength lies largely in finishing medicines from imported inputs. Asymmetric synthesis needs advanced catalysts, process chemists and quality systems, the capability the PLI aims to build. Without it, India pays others for the hardest and most profitable step.

Possible Mains question

Explain why a drug molecule’s “handedness” matters, and how asymmetric synthesis can strengthen India’s self-reliance in active pharmaceutical ingredients. (15 marks, 250 words)

Model approach

  1. Directive — Explain. Clarify the concept, then link it to policy.
  2. Introduction — one molecule, two hands. Define chirality; cite the 2026 Nobel.
  3. Body — the wrong hand can harm. Thalidomide; chiral enzymes and receptors. Draw two mirror molecules fitting or failing a receptor.
  4. Body — direct synthesis is cheaper and cleaner. Kagan’s amplification and Soai’s autocatalysis replace costly separation. Value addition: 2001 Nobel lineage.
  5. Body — India must move up to API chemistry. PLI for bulk drugs and bulk drug parks need catalysis skills.
  6. Conclusion — chemistry as strategic capacity. Pair research funding with strict single-form drug testing.

Administrator's brainstorm

As a State Drugs Controller, a firm switches to a new asymmetric route for a chiral drug. What do you check?

I would ask whether the product’s purity and its share of the unwanted form match the approved specification. If the impurity profile changed, I would require fresh stability and bioequivalence data before release. Cheaper chemistry is welcome; unchecked change is not.